Aug 11, 2026 06:53AM
May 21, 2026 05:00PM
May 21, 2026 05:00PM
May 12, 2026 07:00AM
Sep 2, 2025 07:03AM
May 29, 2025 06:59AM
Nov 24, 2024 07:27PM Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors
Jan 8, 2024 08:14AM
Jan 8, 2024 08:12AM
Dec 5, 2023 12:32PM
Dec 5, 2023 12:27PM
Oct 12, 2023 07:02AM
Oct 12, 2023 07:01AM
Oct 10, 2023 07:02AM Olema Pharmaceuticals (OLMA) Announces Expansion of Collaboration Agreement with Novartis
Oct 10, 2023 07:00AM
Sep 20, 2023 07:29AM
Sep 20, 2023 07:29AM
Sep 6, 2023 04:30PM
Sep 5, 2023 07:31AM
Sep 5, 2023 07:30AM
Aug 8, 2023 04:03PM Olema Oncology Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Aug 2, 2023 04:30PM
Aug 1, 2023 08:00AM
Jul 5, 2023 07:30AM
Jun 2, 2023 04:30PM
May 30, 2023 04:30PM
May 11, 2023 08:44AM
May 11, 2023 08:43AM Olema Oncology Announces OP-1250 Continues to Demonstrate Attractive Combinability with CDK4/6 Inhibitor Palbociclib in Phase 1b/2 Study
May 9, 2023 04:01PM
May 8, 2023 07:06AM
May 2, 2023 04:30PM
Apr 13, 2023 04:30PM
Apr 4, 2023 04:30PM
Mar 9, 2023 04:00PM
Mar 2, 2023 05:00PM Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 2, 2023 04:05PM
Feb 22, 2023 06:11PM
Feb 21, 2023 04:30PM
Feb 2, 2023 06:00PM
Jan 4, 2023 04:30PM
Jan 3, 2023 07:00AM
Dec 7, 2022 03:39PM Olema Pharmaceuticals (OLMA) Announces OP-1250 Demonstrates Attractive Combinability with CDK 4/6 Inhibitor Palbociclib in Phase 1b Dose Escalation Study
Dec 7, 2022 03:37PM
Dec 2, 2022 04:30PM
Nov 21, 2022 09:16AM
Nov 8, 2022 04:30PM
Nov 2, 2022 04:30PM
Nov 1, 2022 08:00AM
Oct 26, 2022 05:50AM Olema (OLMA) Reports Continuous Robust Activity of OP-1250 in Phase 1/2 Trial
Oct 26, 2022 03:00AM

327,987 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All